Literature DB >> 10704712

Primary lymphoepithelioma-like carcinoma of the lung.

A Barroso1, R Nogueira, H Lencastre, J Seada, B Parente.   

Abstract

Lymphoepithelioma is an undifferentiated carcinoma with prominent lymphoid stroma in the nasopharynx. Tumors with similar histology have been reported with other localizations, including the lungs, and are designated as lymphoepithelioma-like carcinomas (LELC). Primary LELC of the lung is very rare, and scant information is available in the scientific literature. This paper details the case of a 25-year-old Caucasian male patient with the diagnosis (determined by thoracotomy) of primary LELC of the lung. Immunohistochemical analysis was negative for Epstein-Barr virus, as was the in situ hybridization of the tumor cells. Observation of the nasopharynx and a magnetic resonance image of the cavum were normal. Because the tumor (T4N2M0) could not be resected, the patient was treated with chemotherapy, carboplatin/5-fluorouracil, completing two cycles. The patient's condition worsened when he developed contralateral pneumonia, which was then followed by pericardial effusion. The patient died 36 h later from cardiac tamponade. Presented here is a revision of this rare pathology, not often reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704712     DOI: 10.1016/s0169-5002(99)00126-9

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  2 in total

1.  Lymphoepithelioma-like carcinoma of the lung: case in which the patient has been followed up for 7 years postoperatively.

Authors:  Naoyuki Yoshino; Hirotoshi Kubokura; Shigeo Yamauchi; Yoshiharu Ohaki; Kiyoshi Koizumi; Kazuo Shimizu
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-12

2.  Primary pulmonary lymphoepithelioma-like carcinoma initially diagnosed as squamous metaplasia: A case report and literature review.

Authors:  Yasha Liang; Cheng Shen; Guowei Che; Fengming Luo
Journal:  Oncol Lett       Date:  2015-02-17       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.